Your browser doesn't support javascript.
loading
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.
Valent, Peter; Orazi, Attilio; Savona, Michael R; Patnaik, Mrinal M; Onida, Francesco; van de Loosdrecht, Arjan A; Haase, Detlef; Haferlach, Torsten; Elena, Chiara; Pleyer, Lisa; Kern, Wolfgang; Pemovska, Tea; Vladimer, Gregory I; Schanz, Julie; Keller, Alexandra; Lübbert, Michael; Lion, Thomas; Sotlar, Karl; Reiter, Andreas; De Witte, Theo; Pfeilstöcker, Michael; Geissler, Klaus; Padron, Eric; Deininger, Michael; Orfao, Alberto; Horny, Hans-Peter; Greenberg, Peter L; Arber, Daniel A; Malcovati, Luca; Bennett, John M.
Afiliação
  • Valent P; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria peter.valent@meduniwien.ac.at.
  • Orazi A; Ludwig Boltzmann Institute for Hematology & Oncology, Vienna, Austria.
  • Savona MR; Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, USA.
  • Patnaik MM; Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Onida F; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • van de Loosdrecht AA; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Haase D; Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, the Netherlands.
  • Haferlach T; Clinic of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Elena C; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Pleyer L; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Kern W; 3 Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Paracelsus Medical University, Salzburg, Austria.
  • Pemovska T; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Vladimer GI; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Schanz J; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Keller A; Clinic of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Lübbert M; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
  • Lion T; Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Sotlar K; Children's Cancer Research Institute and Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
  • Reiter A; Institute of Pathology, Paracelsus Medical University, Salzburg, Austria.
  • De Witte T; Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.
  • Pfeilstöcker M; Department of Tumor Immunology-Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Geissler K; Ludwig Boltzmann Institute for Hematology & Oncology, Vienna, Austria.
  • Padron E; 3 Medical Department, Hanusch Hospital, Vienna, Vienna, Austria.
  • Deininger M; Sigmund Freud University, Vienna, Austria.
  • Orfao A; Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Horny HP; Huntsman Cancer Institute & Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
  • Greenberg PL; Servicio Central de Citometría, Centro de Investigación del Cáncer (IBMCC, CSIC-USAL), CIBERONC and IBSAL, Universidad de Salamanca, Salamanca, Spain.
  • Arber DA; Institute of Pathology, Ludwig-Maximilians University, Munich, Germany.
  • Malcovati L; Stanford University Cancer Institute, Stanford, CA, USA.
  • Bennett JM; Department of Pathology, University of Chicago, Chicago, IL, USA.
Haematologica ; 104(10): 1935-1949, 2019 10.
Article em En | MEDLINE | ID: mdl-31048353
ABSTRACT
Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocytic cells and an elevated risk of transforming into acute leukemia. Over the past two decades, our knowledge about the pathogenesis and molecular mechanisms in CMML has increased substantially. In parallel, better diagnostic criteria and therapeutic strategies have been developed. However, many questions remain regarding prognostication and optimal therapy. In addition, there is a need to define potential pre-phases of CMML and special CMML variants, and to separate these entities from each other and from conditions mimicking CMML. To address these unmet needs, an international consensus group met in a Working Conference in August 2018 and discussed open questions and issues around CMML, its variants, and pre-CMML conditions. The outcomes of this meeting are summarized herein and include diag nostic criteria and a proposed classification of pre-CMML conditions as well as refined minimal diagnostic criteria for classical CMML and special CMML variants, including oligomonocytic CMML and CMML associated with systemic mastocytosis. Moreover, we propose diagnostic standards and tools to distinguish between 'normal', pre-CMML and CMML entities. These criteria and standards should facilitate diagnostic and prognostic evaluations in daily practice and clinical studies in applied hematology.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article